2016 American Transplant Congress
MicroRNA-375 and -200c Are a Set of Novel Biomarkers That Can Predict Islet Autotransplantation Outcome.
Introduction: Total pancreatectomy with islet autotransplantation (TPIAT) is an effective treatment for refractive chronic pancreatitis to relieve pain and retain endocrine function. Patient selection is…2016 American Transplant Congress
Rapamycin (RPM) Synergizes with CD154 mAb and DST to Promote Long-Term Vascularized Composite Allograft (VCA) Survival, but Prevents Induction of Donor-Specific Tolerance.
Even though CD154 mAb (MR-1) plus donor splenocyte transfusion (DST) is very effective at inducing tolerance of various allografts, such as those of hearts, kidneys…2016 American Transplant Congress
Zero and One Mismathing for HLA DR10,14,16 Produces Increased Kidney Graft Survival.
Aims: HLA DR matching has shown measureable significant effects in kidney graft survival. Part and parcel of this association is the HLA Class II allele…2016 American Transplant Congress
Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study in Japan.
Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Previous studies and current guidelines have suggested that elderly persons can be living kidney donors; however, reports on elderly donors >70 years old are…2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.
Multi-Organ Transplant Program, University of Toronto, Toronto, ON, Canada.
IntroductionLiving donor liver transplantation (LDLT) can reduce waiting times and potentially decrease drop-out rates for cirrhotic patients with HCC. However, it has also been reported…2016 American Transplant Congress
Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?
Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…2016 American Transplant Congress
Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.
Transplantation, Toronto General Hospital, Toronto, ON, Canada.
Introduction: We compared the impact of estimating graft to recipient body weight ratio (GBWR) with actual body weight (ABW) and ideal body weight (IBW) on…2016 American Transplant Congress
Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.
Background: Medication non-adherence (MNA) is a significant contributor to late graft loss in kidney transplant recipients. The aim of this study was to develop and…
- « Previous Page
- 1
- …
- 169
- 170
- 171
- 172
- 173
- …
- 180
- Next Page »